Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (Rmat) Designation From FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
poseida therapeutics獲得FDA頒發的再生醫學愛文思控股(Rmat)稱號,用於治療復發/難治性多發性骨髓瘤的P-BCMA-ALLO1
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (Rmat) Designation From FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
poseida therapeutics獲得FDA頒發的再生醫學愛文思控股(Rmat)稱號,用於治療復發/難治性多發性骨髓瘤的P-BCMA-ALLO1
譯文內容由第三人軟體翻譯。